肝细胞癌肝切除术前严重并发症与极早期复发风险预测模型的开发与验证
基于国际多机构数据库2000至2023年969例根治性肝切除肝细胞癌患者,开发并外部验证术前预测严重并发症(Clavien-Dindo≥III级)和极早期复发(术后6个月内)的模型。多因素分析显示ASA>2级和白蛋白-胆红素评分较高与严重并发症相关,白蛋白-胆红素评分较高和肿瘤负荷评分较高与极早期复发相关。极早期复发模型可将患者分为低、中、高风险组,6个月无复发生存率分别为94.1%、86.0%、67.1%。
要点
- ASA>2级和白蛋白-胆红素评分较高是严重并发症的术前预测因素。
- 白蛋白-胆红素评分较高和肿瘤负荷评分较高是极早期复发的术前预测因素。
- 在线计算器可识别严重并发症风险≥30%且极早期复发高风险的 unfavorable 风险特征患者。
核心结论
- 开发并外部验证了一个易于使用的在线计算器,可对肝细胞癌肝切除患者进行短期和长期风险分层。
- 该工具能识别出严重并发症和极早期复发高风险、可能不太可能从手术切除中获益的患者亚组。
研究设计与样本
- 多机构国际数据库回顾性队列研究,纳入2000至2023年接受根治性肝切除的肝细胞癌患者969例。
- 使用多因素分析评估术前特征与严重并发症(Clavien-Dindo≥III级)和极早期复发(术后6个月内复发)的关联,并开发预测模型进行外部验证。
主要发现
- 969例患者中,97例(10.0%)发生严重并发症,116例(12.0%)出现极早期复发。
- 多因素分析显示,ASA分级>2级和白蛋白-胆红素评分较高与严重并发症相关;白蛋白-胆红素评分较高和肿瘤负荷评分较高与极早期复发相关。
- 极早期复发预测模型将患者分为低风险(6个月无复发生存率94.1%)、中风险(86.0%)和高风险(67.1%)。
- 74例患者(7.6%)具有不利风险特征(严重并发症风险≥30%且极早期复发高风险)。
- 严重并发症模型的区分度:训练集AUC 0.69,外部验证AUC 0.80;极早期复发模型:训练集C-index 0.65,外部验证C-index 0.71。
关键数值与推荐
- 严重并发症定义为Clavien-Dindo分级III级或以上。
- 极早期复发定义为术后6个月内复发。
- 极早期复发风险分层:低风险6个月无复发生存率94.1%,中风险86.0%,高风险67.1%。
- 不利风险特征定义为严重并发症风险≥30%且极早期复发高风险。
临床怎么用
- 术前可使用在线计算器(https://junkawashima.shinyapps.io/HCC_comp_VER/)评估肝细胞癌患者严重并发症和极早期复发风险。
- 对于具有不利风险特征的患者,可考虑个体化治疗决策,权衡手术切除的获益与风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We sought to develop and externally validate a preoperative model for predicting the risk of severe complications and very early recurrence after liver resection for hepatocellular carcinoma. METHODS: Patients who underwent curative-intent hepatectomy for hepatocellular carcinoma between 2000 and 2023 were identified using a multi-institutional international database. Preoperative characteristics were assessed in relation to severe complications (defined as complications with a Clavien-Dindo classification III or greater) and very early recurrence (recurrence within 6 months after surgery) using multivariable analysis. Predictive models for severe complications and very early recurrence were developed and externally validated. RESULTS: Among 969 patients, 97 patients (10.0%) experienced severe complications, and 116 patients (12.0%) developed very early recurrence. On multivariable analysis, American Society of Anesthesiologists class >2 and greater albumin-bilirubin score were associated with severe complications. Meanwhile, a greater albumin-bilirubin score and higher tumor burden score were associated with very early recurrence. A predictive model for very early recurrence was able to stratify patients relative to their risk for recurrence: low-risk (6-month recurrence-free survival, 94.1%), medium-risk (6-month recurrence-free survival, 86.0%), and high-risk (6-month recurrence-free survival, 67.1%). A total of 74 patients (7.6%) had an unfavorable risk profile (severe complication risk ≥30% and high-risk for very early recurrence). The discriminative accuracy of the severe complications (training: area under the curve, 0.69; external validation: area under the curve, 0.80) and very early recurrence (training: C-index: 0.65; external validation: C-index: 0.71) models were favorable (see online calculator: https://junkawashima.shinyapps.io/HCC_comp_VER/). CONCLUSION: An easy-to-use online calculator stratified patients relative to short- and long-term risks, identifying a subset of patients at a high risk of severe complications and very early recurrence who were unlikely to benefit from surgical resection.
引用
- Kawashima J, Endo Y, Khalil M, et al. Development and validation of a preoperative risk prediction model for severe complications and very early recurrence after liver resection for hepatocellular carcinoma. Surgery. 2025. PMID: 40577898. doi:10.1016/j.surg.2025.109527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。